On December 22nd, Shanghai Laishi announced that the company has received a notice from its controlling shareholder, Haiyingkang (Qingdao) Medical Technology Co., Ltd., that it is planning to merge and absorb Shanghai Laishi through the issuance of A-shares by Haier Biology to all shareholders of Shanghai Laishi, and raise matching funds through the issuance of A-shares. The company’s stock is scheduled to be suspended from trading starting from December 23, 2024, with an expected suspension period of no more than 10 trading days.
Scan code to share